CBR4 Activators

Common CBR4 Activators include, but are not limited to Retinoic Acid, all trans CAS 302-79-4, Resveratrol CAS 501-36-0, Quercetin CAS 117-39-5, Curcumin CAS 458-37-7 and N-Acetyl-L-cysteine CAS 616-91-1.

CBR4, known as Carbonyl Reductase 4, is intricately woven into several biological pathways, prominently in metabolism and fatty acyl-CoA biosynthesis. This protein-coding gene has associations with specific diseases, notably Bile Acid Synthesis Defect, Congenital, 5, and Horner's Syndrome. As a mitochondrial NADPH-dependent reductase, CBR4 is specialized for o- and p-quinones, exhibiting a broad spectrum of enzymatic activities. These range from 3-oxoacyl-[acyl-carrier-protein] reductase (NADPH) activity and NADPH binding activity to NADPH dehydrogenase (quinone) activity. Such diverse functionalities highlight its importance in the fatty acid biosynthesis process, glycoside metabolism, and protein tetramerization.

Given the pivotal role of CBR4 in these processes, activators targeting this enzyme could significantly influence cellular metabolic activities. Such activators might aim to enhance the enzyme's substrate affinity, increase its catalytic efficiency, or augment the overall expression of the CBR4 gene. By doing so, they could bolster the metabolic pathways CBR4 is involved in, potentially optimizing the synthesis of fatty acids or improving the efficiency of associated metabolic processes. Moreover, in the context of diseases related to CBR4, these activators could offer a means to modulate the gene's activity, thereby influencing disease progression or manifestation. However, a comprehensive understanding of these interactions, and their potential cellular and systemic implications, is essential to predict the broader biochemical and physiological outcomes of CBR4 activation.